AAAAAA

   
Results: 1-13 |
Results: 13
LYMPH-NODE METASTASES FROM LARYNGEAL AND PHARYNGEAL CARCINOMAS - CALCULATION OF BURDEN OF METASTASIS AND ITS IMPACT ON PROGNOSIS
Authors: JAKOBSEN J HANSEN O JORGENSEN KE BASTHOLT L
Citation: J. Jakobsen et al., LYMPH-NODE METASTASES FROM LARYNGEAL AND PHARYNGEAL CARCINOMAS - CALCULATION OF BURDEN OF METASTASIS AND ITS IMPACT ON PROGNOSIS, Acta oncologica (Stockholm), 37(5), 1998, pp. 489-493
A RANDOMIZED DOUBLE-BLIND PHASE-III STUDY OF NIMORAZOLE AS A HYPOXIC RADIOSENSITIZER OF PRIMARY RADIOTHERAPY IN SUPRAGLOTTIC LARYNX AND PHARYNX CARCINOMA, RESULTS OF THE DANISH HEAD AND NECK-CANCER STUDY (DAHANCA) PROTOCOL-5-85
Authors: OVERGAARD J HANSEN HS OVERGAARD M BASTHOLT L BERTHELSEN A SPECHT L LINDELOV B JORGENSEN K
Citation: J. Overgaard et al., A RANDOMIZED DOUBLE-BLIND PHASE-III STUDY OF NIMORAZOLE AS A HYPOXIC RADIOSENSITIZER OF PRIMARY RADIOTHERAPY IN SUPRAGLOTTIC LARYNX AND PHARYNX CARCINOMA, RESULTS OF THE DANISH HEAD AND NECK-CANCER STUDY (DAHANCA) PROTOCOL-5-85, Radiotherapy and oncology, 46(2), 1998, pp. 135-146
PROGNOSTIC FACTORS IN PAPILLARY AND FOLLICULAR THYROID CARCINOMAS - P53 EXPRESSION IS A SIGNIFICANT INDICATOR OF PROGNOSIS
Authors: GODBALLE C ASSCHENFELDT P JORGENSEN KE BASTHOLT L CLAUSEN PP HANSEN TP HANSEN O BENTZEN SM
Citation: C. Godballe et al., PROGNOSTIC FACTORS IN PAPILLARY AND FOLLICULAR THYROID CARCINOMAS - P53 EXPRESSION IS A SIGNIFICANT INDICATOR OF PROGNOSIS, The Laryngoscope, 108(2), 1998, pp. 243-249
LYMPH-NODE METASTASES FROM LARYNGEAL AND PHARYNGEAL CARCINOMAS - CALCULATION OF BURDEN OF METASTASIS AND ITS IMPACT ON PROGNOSIS
Authors: JAKOBSEN J HANSEN O JORGENSEN KF BASTHOLT L
Citation: J. Jakobsen et al., LYMPH-NODE METASTASES FROM LARYNGEAL AND PHARYNGEAL CARCINOMAS - CALCULATION OF BURDEN OF METASTASIS AND ITS IMPACT ON PROGNOSIS, British Journal of Cancer, 77, 1998, pp. 418-418
CLINICAL AND MICROBIOLOGICAL EVALUATION OF RADIOTHERAPY (RT) INDUCED MUCOSITIS IN HEAD AND NECK-CANCER PATIENTS
Authors: HOLMSKOV K GAGHRNHANSEN B HANSEN O BASTHOLT L
Citation: K. Holmskov et al., CLINICAL AND MICROBIOLOGICAL EVALUATION OF RADIOTHERAPY (RT) INDUCED MUCOSITIS IN HEAD AND NECK-CANCER PATIENTS, European journal of cancer, 33, 1997, pp. 828-828
CONVENTIONAL RADIOTHERAPY AS PRIMARY-TREATMENT OF SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK, A RANDOMIZED MULTICENTER STUDY OF 5 VERSUS 6 FRACTIONS PER WEEK - REPORT FROM THE DAHANCA-7 TRIAL
Authors: OVERGAARD J HANSEN HS OVERGAARD M BASTHOLT L SPECHT L EVENSEN J PEDERSEN M GRAU C JORGENSEN K HANSEN O SAPRU W BERTHELSEN A
Citation: J. Overgaard et al., CONVENTIONAL RADIOTHERAPY AS PRIMARY-TREATMENT OF SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK, A RANDOMIZED MULTICENTER STUDY OF 5 VERSUS 6 FRACTIONS PER WEEK - REPORT FROM THE DAHANCA-7 TRIAL, International journal of radiation oncology, biology, physics, 39(2), 1997, pp. 188-188
OSSEOINTEGRATED IMPLANTS FOR PROSTHETIC REHABILITATION AFTER TREATMENT OF CANCER OF THE ORAL CAVITY
Authors: MARKER P SIEMSSEN SJ BASTHOLT L
Citation: P. Marker et al., OSSEOINTEGRATED IMPLANTS FOR PROSTHETIC REHABILITATION AFTER TREATMENT OF CANCER OF THE ORAL CAVITY, Acta oncologica, 36(1), 1997, pp. 37-40
IMPORTANCE OF OVERALL TREATMENT TIME FOR THE OUTCOME OF RADIOTHERAPY OF ADVANCED HEAD AND NECK-CARCINOMA - DEPENDENCY ON TUMOR DIFFERENTIATION
Authors: HANSEN O OVERGAARD J HANSEN HS OVERGAARD M HOYER M JORGENSEN KE BASTHOLT L BERTHELSEN A
Citation: O. Hansen et al., IMPORTANCE OF OVERALL TREATMENT TIME FOR THE OUTCOME OF RADIOTHERAPY OF ADVANCED HEAD AND NECK-CARCINOMA - DEPENDENCY ON TUMOR DIFFERENTIATION, Radiotherapy and oncology, 43(1), 1997, pp. 47-51
DOSE-RESPONSE RELATIONSHIP OF EPIRUBICIN IN THE TREATMENT OF POSTMENOPAUSAL PATIENTS WITH METASTATIC BREAST-CANCER - A RANDOMIZED STUDY OF EPIRUBICIN AT 4 DIFFERENT DOSE LEVELS PERFORMED BY THE DANISH BREAST-CANCER COOPERATIVE GROUP
Authors: BASTHOLT L DALMARK M GJEDDE SB PFEIFFER P PEDERSEN D SANDBERG E KJAER M MOURIDSEN HT ROSE C NIELSEN OS JAKOBSEN P BENTZEN SM
Citation: L. Bastholt et al., DOSE-RESPONSE RELATIONSHIP OF EPIRUBICIN IN THE TREATMENT OF POSTMENOPAUSAL PATIENTS WITH METASTATIC BREAST-CANCER - A RANDOMIZED STUDY OF EPIRUBICIN AT 4 DIFFERENT DOSE LEVELS PERFORMED BY THE DANISH BREAST-CANCER COOPERATIVE GROUP, Journal of clinical oncology, 14(4), 1996, pp. 1146-1155
THE IMPORTANCE OF OVERALL TREATMENT TIME FOR THE OUTCOME OF RADIOTHERAPY OF ADVANCED HEAD AND NECK-CARCINOMA IS DEPENDENT ON TUMOR DIFFERENTIATION
Authors: HANSEN O OVERGAARD J HANSEN HS OVERGAARD M JORGENSEN K BASTHOLT L BERTHELSEN A
Citation: O. Hansen et al., THE IMPORTANCE OF OVERALL TREATMENT TIME FOR THE OUTCOME OF RADIOTHERAPY OF ADVANCED HEAD AND NECK-CARCINOMA IS DEPENDENT ON TUMOR DIFFERENTIATION, European journal of cancer, 31A, 1995, pp. 390-390
THE PHARMACOKINETICS OF HIGH-DOSE EPIRUBICIN AND OF THE CARDIOPROTECTOR ADR-529 GIVEN TOGETHER WITH CYCLOPHOSPHAMIDE, 5-FLUOROURACIL, AND TAMOXIFEN IN METASTATIC BREAST-CANCER PATIENTS
Authors: JAKOBSEN P SORENSEN B BASTHOLT L MIRZA MR GJEDDE SB MOURIDSEN HT ROSE C
Citation: P. Jakobsen et al., THE PHARMACOKINETICS OF HIGH-DOSE EPIRUBICIN AND OF THE CARDIOPROTECTOR ADR-529 GIVEN TOGETHER WITH CYCLOPHOSPHAMIDE, 5-FLUOROURACIL, AND TAMOXIFEN IN METASTATIC BREAST-CANCER PATIENTS, Cancer chemotherapy and pharmacology, 35(1), 1994, pp. 45-52
THE CARDIOPROTECTOR ADR-529 AND HIGH-DOSE EPIRUBICIN GIVEN IN COMBINATION WITH CYCLOPHOSPHAMIDE, 5-FLUOROURACIL, AND TAMOXIFEN - A PHASE-I STUDY IN METASTATIC BREAST-CANCER
Authors: SORENSEN B BASTHOLT L MIRZA MR GJEDDE SB JAKOBSEN P MOURIDSEN HT ROSE C
Citation: B. Sorensen et al., THE CARDIOPROTECTOR ADR-529 AND HIGH-DOSE EPIRUBICIN GIVEN IN COMBINATION WITH CYCLOPHOSPHAMIDE, 5-FLUOROURACIL, AND TAMOXIFEN - A PHASE-I STUDY IN METASTATIC BREAST-CANCER, Cancer chemotherapy and pharmacology, 34(5), 1994, pp. 439-443
INFLUENCE OF LATE SIDE-EFFECTS UPON DAILY-LIFE AFTER RADIOTHERAPY FORLARYNGEAL AND PHARYNGEAL CANCER
Authors: JENSEN AB HANSEN O JORGENSEN K BASTHOLT L
Citation: Ab. Jensen et al., INFLUENCE OF LATE SIDE-EFFECTS UPON DAILY-LIFE AFTER RADIOTHERAPY FORLARYNGEAL AND PHARYNGEAL CANCER, Acta oncologica, 33(5), 1994, pp. 487-491
Risultati: 1-13 |